Unknown

Dataset Information

0

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.


ABSTRACT: Regulated phosphorylation by protein tyrosine kinases (PTKs), such as c-Abl, is critical to cellular homeostasis. In turn, once deregulated as in the chronic myeloid leukemia (CML) fusion protein Bcr-Abl, PTKs can promote cancer onset and progression. The dramatic success of the Bcr-Abl inhibitor imatinib as therapy for CML has inspired interest in other PTKs as targets for cancer drug discovery. Here we report a novel PTK activity and inhibition screening method using hydrogel-immobilized peptide substrates. Using acrylate crosslinkers, we tether peptides via terminal cysteines to thiol-presenting hydrogels in 96-well plates. These surfaces display low background and high reproducibility, allowing semiquantitative detection of peptide phosphorylation by recombinant c-Abl or by Bcr-Abl activity in cell extracts using traditional anti-phosphotyrosine immunodetection and chemifluorescence. The capabilities of this assay are demonstrated by performing model screens for inhibition with several commercially available PTK inhibitors and a collection of pyridopyrimidine Src/Abl dual inhibitors. This assay provides a practical method to measure the activity of a single kinase present in a whole cell lysate with high sensitivity and specificity as a valuable means for efficient small molecule screening.

SUBMITTER: Wu D 

PROVIDER: S-EPMC2291073 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Wu Ding D   Mand Michael R MR   Veach Darren R DR   Parker Laurie L LL   Clarkson Bayard B   Kron Stephen J SJ  

Analytical biochemistry 20071225 1


Regulated phosphorylation by protein tyrosine kinases (PTKs), such as c-Abl, is critical to cellular homeostasis. In turn, once deregulated as in the chronic myeloid leukemia (CML) fusion protein Bcr-Abl, PTKs can promote cancer onset and progression. The dramatic success of the Bcr-Abl inhibitor imatinib as therapy for CML has inspired interest in other PTKs as targets for cancer drug discovery. Here we report a novel PTK activity and inhibition screening method using hydrogel-immobilized pepti  ...[more]

Similar Datasets

| S-EPMC6481090 | biostudies-literature
| S-EPMC4045327 | biostudies-literature
2006-03-31 | GSE2810 | GEO
| S-EPMC2174184 | biostudies-literature
| S-EPMC4027549 | biostudies-literature
| S-EPMC1895816 | biostudies-other
| S-EPMC3202669 | biostudies-literature
| S-EPMC7891886 | biostudies-literature